Date: 2016-12-10
Type of
information: Presentation of results at a congress
phase: 1-2
Announcement: presentation of results at the 2016 San Antonio Breast Cancer Symposium
Company: Corcept Therapeutics (USA - CA)
Product: Korlym® (mifepristone)
Action
mechanism:
- glucocorticoid receptor antagonist. Korlym® is a glucocorticoid receptor antagonist that is indicated to control hyperglycemia associated with Cushing's syndrome, a rare, debilitating endocrine disorder.
Disease: metastatic triple negative breast cancer (TBNC)
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On December 10, 2016, Corcept Therapeutics released efficacy data from its Phase 1/2 trial of mifepristone to treat patients with metastatic (TNBC). The data were presented at the 2016 San Antonio Breast Cancer Symposium.
- This open-label trial was designed to investigate whether the addition of mifepristone enhances the effect of eribulin (Halaven®) in patients with TNBC whose tumors express GR, one of the receptors to which mifepristone binds.
- The trial studied 21 patients with GR positive tumors, one with a GR negative tumor and one whose GR status is not known. As determined using the Response Evaluation Criteria in Solid Tumors (RECIST), efficacy results in this group were as follows: Four patients exhibited a partial response, defined as a 30 percent or greater reduction in tumor size, eight had stable disease and 11 had progressive disease. One patient (who has exhibited a partial response) continues on therapy (see Figure 1).
"
Is
general: Yes
